The symbol of Biogen Pharmachem Industries ... Niraj Vaghela is chairman and Khushboo Khandelwal is the company secretary for Biogen Pharmachem Industries Ltd. Zero income tax: Investment in ...

Biogen expects 2025 non-GAAP EPS of $15.25-$16.25 and a mid-single-digit decline in total revenue, primarily due to MS franchise pressures, including potential biosimilar and generic entries. Growth ...

While the continued erosion of Biogen’s multiple sclerosis franchise and weaker-than-expected 2025 guidance doesn’t seem to ...

Stifel analyst Paul Matteis lowered the firm’s price target on Biogen (BIIB) to $144 from $175 and keeps a Hold rating on the shares. The ...

The funding agreement comes as Biogen revealed a modest Q4 sales beat, which analysts expect will be “overshadowed” by the ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

The agreement hands Biogen as much as $250 million in exchange for milestone payments and sales royalties for litifilimab, which is in a pair of late-stage studies in lupus.

Biogen Inc. closed 41.43% below its 52-week high of $238.00, which the company achieved on July 12th.

Biogen (BIIB) stock was granted a Market Perform recommendation by Bernstein ahead of Q4 earnings, citing concerns over its Alzheimer's drug sales. Read more here.

Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Looking at the universe of stocks we cover at Dividend Channel, on 2/11/25, Baker Hughes Company (Symbol: BKR) will trade ex-dividend, for its quarterly dividend of $0.23, payable on 2/21/25.